EUCTR2004-000243-23-DK进行中（未招募）1 期
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma - HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Patients must have a diagnostic biopsy of non-cutaneous T-cell lymphoma with a CD4 positive phenotype. The biopsy must be performed within 6 months of first treatment. Patients must be diagnosed according to one of the following subgroups by histological subtypes as defined by WHO:
- •Peripheral T-cell lymphoma (PTCL) unspecified
- •Angioimmunnoblastic T-cell lymphoma
- •Anaplastic large cell lymphoma
- •Enteropathy type T-cell lymphoma
- •Hepatosplenic T-cell lymphoma
- •2.Relapse or refractory to at least one prior chemotherapy. Refractory is defined as resistance to therapy due to lack of response or progression of disease. The relapse must be histologically confirmed. The histology should be determined through an excisional lymph node biopsy. In case this is not feasiable due to different standard practice or not possible in case of more deeply located etc. a core biopsy can be performed.
- •3.CT scan at screening showing:
- •a)2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or
- •b)1 clearly demarcated lesion of a largest diameter = 2.0 cm
- •c)For patients with PTCL, hepatosplenic type, liver and/or spleen must be enlarged and the case must be immunohistochemically confirmed as being CD4-positive.
- •d) For patients with PTCL, enteropathy type, a bioptic verification with immunohistochemically confirmed CD4-positivity must also be present.
- •4.Age =18
- •5.Following receipt of verbal and written information about the trial, the
- •patient must provide signed consent before any trial related activity is
- •carried out.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Prior treatment with anti-CD4 monoclonal antibodies.
- •2)Treatment with CdA , fludarabine or Campath® within the previous year.
- •3)Treatment within 4 weeks prior to visit 2 with systemic anticancer therapies, such as, but not limited to: methorexate, bleomycin, cyclophosphamide, systemic glucocorticosteroids.
- •4)Relapse after more than two previous lymphoma treatment regimens (high dose consolidation is not regarded as a regimen itself).
- •5)Leukemia.
- •6)Life expectancy less then 6 months.
- •7)WHO performance status = 3
- •8)Concurrent or previous malignancies within the past 5 years except adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell skin cercinoma.
- •9)Acute or chronic infectious disease requiring systemic medication.
- •10)Significant concurrent, uncontrolled or active medical condition including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric disease.
- •11)Screening laboratory values
- •i.Hemoglobin < 5.3 mmol/L (<8.7 g/dL)
- •ii.WBC =2.5 x 109 cells/L
- •iii.Neutrophils< 1.5 x 109cells/L
- •iv.Platelets < 75 x 109 cells/L
- •v.CD3+CD4+ cell count > 2000 cells/mm3
- •vi.ALT/AST > 4 times upper limit of normal, unless lymphoma related
- •vii.S-creatinine greater than 133 µmmol/L
- •12)Known or suspected positive serology for HIV.
- •13)Allogenic bone marrow transplantation.
- •14)Known or clinical suspicion for CNS involvement.
- •15)Breast-feeding women or women with a positive pregnancy test at visit 1.
- •16)Women of childbearing potential not using either hormonal birth control or an intrauterine device for the entire trial period.
- •17)Simultaneous or previous participation in a trial with any investigational drug within 4 weeks prior to start of trial treatment.
- •18)Patients known or suspected of being not able to comply with the requirements of the trial (e.g due to alcoholism, drug dependency or psychological disorder).
研究者
相似试验
进行中（未招募）
不适用
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma - HuMax-CD4 in Non-Cutaneous T-Cell LymphomaThe mature non-cutaneous T-cell lymphomas expressing the CD4 molecule are the object of this protocol. 1.Peripheral T-cell lymphoma (PTCL) unspecified2.Angioimmunnoblastic T-cell lymphoma3.Anaplastic large cell lymphoma4.Enteropathy type T-cell lymphoma5.Hepatosplenic T-cell lymphoma.MedDRA version: 7.0Level: LLTClassification code 10042971EUCTR2004-000243-23-SEGenmab A/S20
已完成
1 期
A clinical study to see the effect of an Ayurvedic formulation in comparison with Olopatadine (0.1%) Eye Drop in allergic conjunctivitisCTRI/2019/03/018185Sane Guruji Arogya Kendra
进行中（未招募）
1 期
Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infectioEUCTR2020-001310-38-DEDRK-Bluspendedienst Baden-Württemberg - Hessen gGmbH120
尚未招募
1 期
To study the effect of Tulasi Swarasadi Taila Nasya and Sodium chloride (0.65%) nasal spray in Allergic rhinitisCTRI/2019/06/019739Sane Guruji Arogya Kendra
进行中（未招募）
1 期
A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old.Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58MedDRA version: 20.0 Level: PT Classification code 10061331 Term: Papilloma viral infection System Organ Class: 10021881 - Infections and infestationsEUCTR2015-005093-38-BEMerck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc1,212